Every Condition We Treat —
and the Evidence Behind It.

We treat conditions across four major categories: addiction (opioids, alcohol, stimulants, kratom, nicotine), mental health (treatment-resistant depression, anxiety, OCD, eating disorders, SSRI discontinuation), trauma (PTSD, C-PTSD, veterans, first responders, TBI), and neurological (Parkinson's, MS, chronic pain). Evidence levels vary by indication — see each condition page for current research and our outcomes.

We label every indication honestly: Established (multiple trials + registry data), Strong (strong observational data + clear mechanism), Emerging (promising case series, early trials), or Investigational (theoretical + individual reports). This is the same calibration our medical team uses internally — we will not market an experimental application as proven.

Yes — most of our patients have comorbid conditions (e.g., opioid use disorder + depression + PTSD). Ibogaine's mechanism (5-HT, μ-opioid, σ-1, NMDA, neurotrophic) addresses multiple targets simultaneously, which is part of its clinical appeal. Our medical team designs combined protocols around your specific comorbidity profile.

Yes. Ibogaine is contraindicated in active psychosis, certain cardiac conditions (significant QTc prolongation, structural heart disease, untreated arrhythmia), unstable seizure disorders, and during pregnancy. It is not a substitute for cancer treatment, primary surgical intervention, or acute psychiatric crisis stabilization. Our screening identifies these contraindications during admissions.

Ibogaine is a pleiotropic agent — it acts at multiple receptor systems (5-HT, μ-opioid, NMDA, σ-1, nicotinic), upregulates neurotrophic factors (GDNF, BDNF), modulates neuroinflammation, and induces a 6-12 hour psycho-experiential state that supports trauma processing. This combination is why a single drug shows efficacy across addiction, mood, trauma, and neurological conditions.

Our /ibogaine-research-hub aggregates the published literature, our case studies, and our internal outcomes data. Every condition page also links the specific studies most relevant to that indication.